Prohost Biotech
HomeArticlesToday's HighlightsAbout Nektar’s product NKTR- 214 at ASCO
Today's Highlights
Premium

About Nektar’s product NKTR- 214 at ASCO

The real news coming from the presentation at ASCO related to the combination of   Nektar Therapeutics (NKTR)  and   Bristol-Myers Squibb (BMY)  was viewed as positive by many analysts and investor un...
P

Prohost Biotech

1 min read
2
0

Unlock Premium Content

This article contains exclusive content for our premium subscribers. Join our community to access in-depth research, expert insights, and comprehensive analysis.

Unlimited articles
Expert analysis
Research reports

Tags

American Society of Clinical Oncology (ASCO)
Bristol-Myers Squibb (BMY)
Nektar Therapeutics (NKTR)

Comments (0)

Please sign in to join the discussion

Related Articles

Today's Highlights
Premium

Lilly to acquire Centessa Pharmaceuticals to Advance Treatments for Sleep-Wake Disorders

Eli Lilly & Centessa Pharmaceuticals Story March 31, 2026 /PRNewswire/ -- Eli Lilly and Company ( LLY ) and Centessa Pharmaceuticals plc ( CNTA ) announced a definitive agreement for Lilly to acquire...
P

Prohost Biotech

Mar 31, 2026

1m
85
Today's Highlights
Premium

Biogen: FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

Biogen in the NEWS Today,  March 30, 2026, Biogen Inc ( BIIB ) announced that the High Dose Regimen of SPINRAZA® (nusinersen), which is comprised of 50 mg/5 mL and 28 mg/5 mL doses, was approved by th...
P

Prohost Biotech

Mar 30, 2026

1m
77
Today's Highlights
Premium

Rocket Pharmaceuticals Announced FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I

Rocket Pharmaceuticals in the NEWS March 27, 2026, Rocket Pharmaceuticals ( RCKT ) announced that the U.S. FDA has granted accelerated approval for KRESLADI™ (marnetegragene autotemcel), an autologous...
P

Prohost Biotech

Mar 27, 2026

1m
61